Your search for ‘Smart & Biggar’ returned 2,497 results

The Superior Court confirmed that non-French trademarks on store-front signage do not need to be accompanied by a descriptor of the nature of the business.

As we previously reported, the Ontario Court of Appeal affirmed the lower court's decision dismissing Apotex's claims against Eli Lilly under the Ontario and English Statutes of Monopolies, Trademarks Act...

Merck sought leave to appeal a decision of the Federal Court of Appeal (2021 FCA 224) affirming a Federal Court decision upholding Health Canada's refusal to add a patent relating to a formulation of Merck's KEYTRUDA...

On January 8, 2021, the Supreme Court of Canada denied leave to Janssen and Kennedy Trust (Docket No. 39099) with respect to the Federal Court

Mark Robbins and François Larose write for World Trademark Review's Country Correspondents - Canada section,

The world of digital marketing & advertising is fast-paced and always evolving to adopt the latest technology and capitalize on pop culture trends and new media channels.

In October 2020, the Pharmaceutical Advertising Advisory Board (PAAB) released an advisory addressing references to "no sub" or "no substitution" in advertising materials.

On February 1, 2023, the Minister of Health announced the appointment of Thomas J. Digby as the new Chairperson for the Patented Medicine Prices Review Board (PMPRB)...

Principals Ainslie Parsons and Noel Courage, along with expert international coauthors, recently contributed to an article in The Patent Lawyer Magazine examining how plant breeders and biotechs can protect...

The following are highlights of developments in Canadian life sciences intellectual property and regulatory law in 2016, updating our 2016 mid-year highlights.

The Federal Court of Appeal ("FCA") has ordered a new trial in the STELARA litigation. As reported in the January 20, 2014 issue of IP Update — Canada, earlier this year Justice Hughes of the Federal Court concluded that Janssen Inc (Janssen)'s antibody drug STELARA (ustekinumab) ..

As previously reported, Health Canada conducted stakeholder consultations and analysis of issues related to the naming of biologic drugs, including biosimilars.

New Court Proceedings - October 2018

On February 21, 2018, Justice O'Reilly granted Collegium's motion to strike Purdue's statement of claim for infringement of a patent relating to oxycodone salt ...

As previously reported, on December 2, 2017, Canada's Governor-in-Council published proposed Regulations Amending the Patented Medicines Regulations for comment.

On December 11, 2017, Health Canada announced a guidance document clarifying the requirements for drug submissions and applications to be processed under the administrative pathway.

On February 6, 2018, the Patented Medicine Prices Review Board (PMPRB) announced the publication of the most recent edition of its series of reports on generic drug pricing.

The Canadian Intellectual Property Office (CIPO) will be launching a new online portal for patent services, MyCIPO Patents, on July 15, 2024.